Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LipoCurc with RT and TMZ in High-Grade Gliomas
NCT05768919Phase 2Recruiting
- Sponsor
- SignPath Pharma
- Start
- Mar 2023
- Primary completion
- Feb 2026
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of liposomal curcumin in glioma, sponsored by SignPath Pharma. Primary endpoints: Dose Limiting Toxicity (10 weeks) and Dose Limiting Toxicity (Duration of Treatment) at 34 weeks. Started Mar 2023; status: recruiting.
02
Drugs
liposomal curcumin
03
Conditions
glioma
Beyond the preview
Go deeper on NCT05768919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05768919.